Exhibitor

Interpace Diagnostics is a provider of molecular testing for numerous types of cancer. The Company offers ThyGenX® and ThyraMIR® for indeterminate thyroid nodules; PancraGen® and PanDNA® to help identify those pancreatic cysts most likely to develop in to pancreatic cancer; RespriDx®, a molecular test that differentiates metastasis from new primary lung tumors, and BarreGen®, a molecular test that measures mutational load, enabling physicians to identify cases that are most likely to progress to esophageal cancer.